Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)

Clinical Infectious Diseases

Volumn 63, Issue 12, 2016, Pages E202-E264

  Aronson, Naomi ^a   Herwaldt, Barbara L ^b   Libman, Michael ^c   Pearson, Richard ^d   Lopez Velez, Rogelio ^e   Weina, Peter ^f   Carvalho, Edgar M ^g   Ephros, Moshe ^h   Jeronimo, Selma ⁱ   Magill, Alan ^j  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF VIRGINIA   (United States)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

^g INSTITUTO OSWALDO CRUZ   (Brazil)

^h CARMEL MEDICAL CENTER   (Israel)

ⁱ FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^j BILL AND MELINDA GATES FOUNDATION   (United States)

more..

Author keywords

cutaneous leishmaniasis; immunocompromised host; leishmaniasis diagnostic testing; mucosal leishmaniasis; visceral leishmaniasis

Indexed keywords

HUMAN; LEISHMANIASIS; PRACTICE GUIDELINE;

HUMANS; LEISHMANIASIS;

EID: 85007394415     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw670     Document Type: Article

References (503)

1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
2. Gonzalez U. Cochrane reviews on neglected diseases: The case of cutaneous leishmaniasis. Cochrane Database Syst Rev 2013; 3:Ed000055.
3. Gonzalez U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008; 4:CD005067.
4. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64:380-2.
5. Wortmann GW, Aronson NE, Miller RS, Blazes D, Oster CN. Cutaneous leishmaniasis following local trauma: A clinical pearl. Clin Infect Dis 2000; 31:199-201.
6. Sanchez JL, Diniega BM, Small JW, et al. Epidemiologic investigation of an outbreak of cutaneous leishmaniasis in a defined geographic focus of transmission. Am J Trop Med Hyg 1992; 47:47-54.
7. Puig L, Pradinaud R. Leishmania and HIV co-infection: Dermatological manifestations. Ann Trop Med Parasitol 2003; 97(suppl 1):107-14.
8. Foulet F, Cosnes A, Dellion S, et al. Leishmania major cutaneous leishmaniasis in HIV-positive patients does not spread to extralesional sites. Arch Dermatol 2006; 142:1368-9.
9. Couppie P, Clyti E, Sobesky M, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIVinfected patients in French Guiana. Br J Dermatol 2004; 151:1165-71.
10. Guerra JA, Coelho LI, Pereira FR, et al. American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon. Am J Trop Med Hyg 2011; 85:524-7.
11. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: The second 10 years. Clin Microbiol Rev 2008; 21:334-59, table of contents.
12. Lindoso JA, Barbosa RN, Posada-Vergara MP, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the NewWorld. Br J Dermatol 2009; 160:311-8.
13. Niamba P, Goumbri-Lompo O, Traore A, Barro-Traore F, Soudre RT. Diffuse cutaneous leishmaniasis in an HIV-positive patient in western Africa. Australas J Dermatol 2007; 48:32-4.
14. Niamba P, Traore A, Goumbri-Lompo O, et al. Cutaneous leishmania in HIV patient in Ouagadougou: Clinical and therapeutic aspects [in French]. Ann Dermatol Venereol 2006; 133:537-42.
15. Ndiaye PB, Develoux M, Dieng MT, Huerre M. Diffuse cutaneous leishmaniasis and acquired immunodeficiency syndrome in a Senegalese patient [in French]. Bull Soc Pathol Exot 1996; 89:282-6.
16. Torrico F, Parrado R, Castro R, et al. Co-infection of Leishmania (Viannia) braziliensis and HIV: Report of a case of mucosal leishmaniasis in Cochabamba, Bolivia. Am J Trop Med Hyg 2009; 81:555-8.
17. Mattos M, Caiza A, Fernandes O, et al. American cutaneous leishmaniasis associated with HIV infection: Report of four cases. J Eur Acad Dermatol Venereol 1998; 10:218-25.
18. Mota Sasaki M, Matsumo Carvalho M, Schmitz Ferreira ML, Machado MP. Cutaneous leishmaniasis coinfection in AIDS patients: Case report and literature review. Braz J Infect Dis 1997; 1:142-4.
19. Aoun J, Habib R, Charaffeddine K, Taraif S, Loya A, Khalifeh I. Caseating granulomas in cutaneous leishmaniasis. PLoS Negl Trop Dis 2014; 8:e3255.
20. Ahluwalia S, Lawn SD, Kanagalingam J, Grant H, Lockwood DN. Mucocutaneous leishmaniasis: An imported infection among travellers to central and South America. BMJ 2004; 329:842-4.
21. Camargo RA, Tuon FF, Sumi DV, et al. Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses. Am J Trop Med Hyg 2010; 83:515-8.
22. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg 1986; 80:859-76.
23. Marsden PD. Mucocutaneous leishmaniasis. BMJ 1990; 301:656-7.
24. Figueroa RA, Lozano LE, Romero IC, et al. Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species. J Infect Dis 2009; 200:638-46.
25. Lessa MM, Lessa HA, Castro TW, et al. Mucosal leishmaniasis: Epidemiological and clinical aspects. Braz J Otorhinolaryngol 2007; 73:843-7.
26. Jones TC, Johnson WD Jr, Barretto AC, et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis 1987; 156:73-83.
27. de Oliveira-Neto MP, Mattos MS, Perez MA, et al. American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: Main clinical and epidemiologic characteristics. Int J Dermatol 2000; 39:506-14.
28. Lessa HA, Carvalho EM, Marsden PD. Eustachian tube blockage with consequent middle ear infection in mucosal leishmaniasis. Rev Soc Bras Med Trop 1994; 27:103.
29. Boaventura VS, de Oliveira JG, Costa JM, et al. The value of the otorhinolaryngologic exam in correct mucocutaneous leishmaniasis diagnosis. Am J Trop Med Hyg 2009; 81:384-6.
30. Boggild AK, Valencia BM, Veland N, et al. Non-invasive cytology brush PCR diagnostic testing in mucosal leishmaniasis: Superior performance to conventional biopsy with histopathology. PLoS One 2011; 6:e26395.
31. Magill A. Leishmania species. Chapter 277. In: Principles and practice of infectious diseases. 8th ed. Philadelphia, PA: Elsevier, 2015:3091-107.
32. Magill A. Leishmaniasis. Chapter 99. In: Hunter's TropicalMedicine and Emerging Infectious Diseases. 9th ed. Philadelphia, PA: Saunders Publishing, 2013:739-60.
33. Jeronimo S, de Queiroz Sousa A, Pearson R. Leishmaniasis. In: Tropical Infectious Diseeases: Principles, pathogens, and practice. 2nd ed. Philadelphia, PA: Saunders Publishing, 2006; 1095-113.
34. Jarvis JN, Lockwood DN. Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis 2013; 26:1-9.
35. Albuquerque LC, Mendonca IR, Cardoso PN, et al. HIV/AIDS-related visceral leishmaniasis: A clinical and epidemiological description of visceral leishmaniasis in northern Brazil. Rev Soc Bras Med Trop 2014; 47:38-46.
36. Hurissa Z, Gebre-Silassie S, Hailu W, et al. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health 2010; 15:848-55.
37. Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: Generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95:668-72.
38. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001; 80:54-73.
39. Pasquau F, Ena J, Sanchez R, et al. Leishmaniasis as an opportunistic infection in HIV-infected patients: Determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. Eur J Clin Microbiol Infect Dis 2005; 24:411-8.
40. Lopez-Velez R, Perez-Molina JA, Guerrero A, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 1998; 58:436-43.
41. Rosenthal E, Marty P, del Giudice P, et al. HIV and Leishmania coinfection: A review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 2000; 31:1093-5.
42. World Health Organization. Control of the leishmaniases. World Health Organization technical report series. Geneva, Switzerland: WHO, 2010; 949:xii-xiii, 1-186, back cover.
43. Bosch RJ, Rodrigo AB, Sanchez P, de Galvez MV, Herrera E. Presence of Leishmania organisms in specific and non-specific skin lesions in HIV-infected individuals with visceral leishmaniasis. Int J Dermatol 2002; 41:670-5.
44. Colebunders R, Depraetere K, Verstraeten T, et al. Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection. J Am Acad Dermatol 1999; 41(5 pt 2):847-50.
45. Alsina-Gibert M, Lopez-Lerma I, Martinez-Chamorro E, Herrero-Mateu C. Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient. Arch Dermatol 2006; 142:787-9.
46. Ara M, Maillo C, Peon G, et al. Visceral leishmaniasis with cutaneous lesions in a patient infected with human immunodeficiency virus. Br J Dermatol 1998; 139:114-7.
47. Perrin C, Taillan B, Hofman P, Mondain V, Lefichoux Y, Michiels JF. Atypical cutaneous histological features of visceral leishmaniasis in acquired immunodeficiency syndrome. Am J Dermatopathol 1995; 17:145-50.
48. Gonzalez-Beato MJ, Moyano B, Sanchez C, et al. Kaposi's sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis. Br J Dermatol 2000; 143:1316-8.
49. Farooq U, Choudhary S, Chacon AH, et al. Post-kala-azar dermal leishmaniasis in HIV-infected patients with AIDS: A report of two cases diagnosed in the USA. Int J Dermatol 2013; 52:1098-104.
50. Stark D, Pett S, Marriott D, Harkness J. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient. J Clin Microbiol 2006; 44:1178-80.
51. Bittencourt A, Silva N, Straatmann A, Nunes VL, Follador I, Badaro R. Postkala- A zar dermal leishmaniasis associated with AIDS. Braz J Infect Dis 2002; 6:313-6.
52. Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE. Successful treatment of postkala- A zar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect 2006; 53:e25-7.
53. Catorze G, Alberto J, Afonso A, Vieira R, Cortes S, Campino L. Leishmania infantum/HIV co-infection: Cutaneous lesions following treatment of visceral leishmaniasis [in French]. Ann Dermatol Venereol 2006; 133:39-42.
54. Carnauba D Jr, Konishi CT, Petri V, Martinez IC, Shimizu L, Pereira-Chioccola VL. Atypical disseminated leishmaniasis similar to post-kala-azar dermal leishmaniasis in a Brazilian AIDS patient infected with Leishmania (Leishmania) infantum chagasi: A case report. Int J Infect Dis 2009; 13:e504-7.
55. Herwaldt BL. Leishmaniasis. Lancet 1999; 354:1191-9.
56. Boggild AK, Ramos AP, Valencia BM, et al. Diagnostic performance of filter paper lesion impression PCR for secondarily infected ulcers and nonulcerative lesions caused by cutaneous leishmaniasis. J Clin Microbiol 2011; 49:1097-100.
57. Boggild AK, Ramos AP, Espinosa D, et al. Clinical and demographic stratification of test performance: A pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:345-50.
58. Robinson RJ, Agudelo S, Muskus C, et al. The method used to sample ulcers influences the diagnosis of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2002; 96(suppl 1):S169-71.
59. Ramirez JR, Agudelo S, Muskus C, et al. Diagnosis of cutaneous leishmaniasis in Colombia: The sampling site within lesions influences the sensitivity of parasitologic diagnosis. J Clin Microbiol 2000; 38:3768-73.
60. Navin TR, Arana FE, de Merida AM, Arana BA, Castillo AL, Silvers DN. Cutaneous leishmaniasis in Guatemala: Comparison of diagnostic methods. Am J Trop Med Hyg 1990; 42:36-42.
61. Weigle KA, de Davalos M, Heredia P, Molineros R, Saravia NG, D'Alessandro A. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: A comparison of seven methods. Am J Trop Med Hyg 1987; 36:489-96.
62. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: Current status and future applications. J Clin Microbiol 2007; 45:21-5.
63. Klotz O, Lindenberg H. The pathology of leishmaniosis of the nose. Am J Trop Med Hyg 1923; 3:117-41.
64. Jara M, Adaui V, Valencia BM, et al. Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: Exploratory study of parasite load and clinical parameters. J Clin Microbiol 2013; 51:1826-33.
65. Gomes CM, de Paula NA, Cesetti MV, Roselino AM, Sampaio RN. Mucocutaneous leishmaniasis: Accuracy and molecular validation of noninvasive procedures in a L. (V.) braziliensis-endemic area. Diagn Microbiol Infect Dis 2014; 79:413-8.
66. Hartley MA, Drexler S, Ronet C, Beverley SM, Fasel N. The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis. Trends Parasitol 2014; 30:412-22.
67. Osorio LE, Castillo CM, Ochoa MT. Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: Clinical characteristics. Am J Trop Med Hyg 1998; 59:49-52.
68. Boaventura VS, Cafe V, Costa J, et al. Concomitant early mucosal and cutaneous leishmaniasis in Brazil. Am J Trop Med Hyg 2006; 75:267-9.
69. Turetz ML, Machado PR, Ko AI, et al. Disseminated leishmaniasis: A new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 2002; 186:1829-34.
70. Lessa HA, Lessa MM, Guimaraes LH, et al. A proposed new clinical staging system for patients with mucosal leishmaniasis. Trans R Soc Trop Med Hyg 2012; 106:376-81.
71. Mary C, Faraut F, Drogoul MP, et al. Reference values for Leishmania infantum parasitemia in different clinical presentations: Quantitative polymerase chain reaction for therapeutic monitoring and patient follow-up. Am J Trop Med Hyg 2006; 75:858-63.
72. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002; 9:951-8.
73. da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg 2005; 72:811-4.
74. Thakur CP. A comparison of intercostal and abdominal routes of splenic aspiration and bone marrow aspiration in the diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1997; 91:668-70.
75. Salam MA, Khan MG, Bhaskar KR, Afrad MH, Huda MM, Mondal D. Peripheral blood buffy coat smear: A promising tool for diagnosis of visceral leishmaniasis. J Clin Microbiol 2012; 50:837-40.
76. World Health Organization. Visceral leishmaniasis rapid diagnostic test performance. Diagnostic evaluation series No. 4. Geneva, Switzerland: WHO, 2011. Available at: Http://www.who.int/tdr/publications/documents/vl-rdt-evaluation. pdf. Accessed 22 October 2016.
77. Boelaert M, Verdonck K, Menten J, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev 2014; 6:CD009135.
78. van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am 2012; 26:309-22.
79. Vaish M, Mehrotra S, Chakravarty J, Sundar S. Noninvasive molecular diagnosis of human visceral leishmaniasis. J Clin Microbiol 2011; 49:2003-5.
80. Weina PJ, Neafie RC,Wortmann G, Polhemus M, Aronson NE. OldWorld leishmaniasis: An emerging infection among deployed US military and civilian workers. Clin Infect Dis 2004; 39:1674-80.
81. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010; 8:419-33.
82. Cassagne C, Pratlong F, Jeddi F, et al. Identification of Leishmania at the species level with matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect 2014; 20:551-7.
83. Mouri O, Morizot G, Van der Auwera G, et al. Easy identification of leishmania species by mass spectrometry. PLoS Negl Trop Dis 2014; 8:e2841.
84. Van der Auwera G, Dujardin JC. Species typing in dermal leishmaniasis. Clin Microbiol Rev 2015; 28:265-94.
85. Hodiamont CJ, Kager PA, Bart A, et al. Species-directed therapy for leishmaniasis in returning travellers: A comprehensive guide. PLoS Negl Trop Dis 2014; 8: E2832.
86. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8:191-9.
87. Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: A systematic review. PLoS Negl Trop Dis 2011; 5:e1153.
88. Tavares CA, Fernandes AP, Melo MN. Molecular diagnosis of leishmaniasis. Expert Rev Mol Diagn 2003; 3:657-67.
89. de Ruiter CM, van der Veer C, Leeflang MM, Deborggraeve S, Lucas C, Adams ER. Molecular tools for diagnosis of visceral leishmaniasis: Systematic review and meta-analysis of diagnostic test accuracy. J Clin Microbiol 2014; 52:3147-55.
90. Mary C, Faraut F, Lascombe L, Dumon H. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol 2004; 42:5249-55.
91. Wortmann G, Sweeney C, Houng HS, et al. Rapid diagnosis of leishmaniasis by fluorogenic polymerase chain reaction. Am J Trop Med Hyg 2001; 65:583-7.
92. Odiwuor SO, Saad AA, De Doncker S, et al. Universal PCR assays for the differential detection of all Old World Leishmania species. Eur J Clin Microbiol Infect Dis 2011; 30:209-18.
93. Wortmann G, Hochberg LP, Arana BA, Rizzo NR, Arana F, Ryan JR. Diagnosis of cutaneous leishmaniasis in Guatemala using a real-time polymerase chain reaction assay and the Smartcycler. Am J Trop Med Hyg 2007; 76:906-8.
94. Schonian G, Mauricio I, Cupolillo E. Is it time to revise the nomenclature of Leishmania Trends Parasitol 2010; 26:466-9.
95. Welch RJ, Anderson BL, Litwin CM. Rapid immunochromatographic strip test for detection of anti-K39 immunoglobulin G antibodies for diagnosis of visceral leishmaniasis. Clin Vaccine Immunol 2008; 15:1483-4.
96. Burns JM Jr, Shreffler WG, Benson DR, Ghalib HW, Badaro R, Reed SG. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci USA 1993; 90:775-9.
97. Chappuis F, Rijal S, Soto A, Menten J, Boelaert M. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 2006; 333:723.
98. Sundar S, Sahu M, Mehta H, et al. Noninvasive management of Indian visceral leishmaniasis: Clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis 2002; 35:581-6.
99. Braz RF, Nascimento ET, Martins DR, et al. The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am J Trop Med Hyg 2002; 67:344-8.
100. Vallur AC, Reinhart C, Mohamath R, et al. Accurate serodetection of asymptomatic Leishmania donovani infection by use of defined antigens. J Clin Microbiol 2016; 54:1025-30.
101. Bezuneh A, Mukhtar M, Abdoun A, et al. Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patients. Am J Trop Med Hyg 2014; 91:1109-15.
102. Pattabhi S, Whittle J, Mohamath R, et al. Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis. PLoS Negl Trop Dis 2010; 4.
103. Ritmeijer K, Melaku Y, Mueller M, Kipngetich S, O'Keeffe C, Davidson RN. Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am J Trop Med Hyg 2006; 74:76-80.
104. Gidwani K, Picado A, Ostyn B, et al. Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India. Clin Vaccine Immunol 2011; 18:346-8.
105. Mandal J, Khurana S, Dubey ML, Bhatia P, Varma N, Malla N. Evaluation of direct agglutination test, rk39 Test, and ELISA for the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg 2008; 79:76-8.
106. Kar K. Serodiagnosis of leishmaniasis. Crit Rev Microbiol 1995; 21:123-52.
107. Romero HD, Silva Lde A, Silva-Vergara ML, et al. Comparative study of serologic tests for the diagnosis of asymptomatic visceral leishmaniasis in an endemic area. Am J Trop Med Hyg 2009; 81:27-33.
108. Cota GF, de Sousa MR, Demarqui FN, Rabello A. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: Meta-analysis. PLoS Negl Trop Dis 2012; 6:e1665.
109. ter Horst R, Tefera T, Assefa G, Ebrahim AZ, Davidson RN, Ritmeijer K. Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia. Am J Trop Med Hyg 2009; 80:929-34.
110. Nascimento ET, Moura ML, Queiroz JW, et al. The emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in northeast Brazil. Trans R Soc Trop Med Hyg 2011; 105:298-300.
111. Hartzell JD, Aronson NE,Weina PJ, Howard RS, Yadava A,Wortmann GW. Positive rK39 serologic assay results in US servicemen with cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 79:843-6.
112. Molinet FJ, Ampuero JS, Costa RD, Noronha EF, Romero GA. Specificity of the rapid rK39 antigen-based immunochromatographic test Kalazar Detect(r) in patients with cutaneous leishmaniasis in Brazil. Mem Inst Oswaldo Cruz 2013; 108.
113. Andrade-Narvaez FJ, Medina-Peralta S, Vargas-Gonzalez A, Canto-Lara SB, Estrada-Parra S. The histopathology of cutaneous leishmaniasis due to Leishmania (Leishmania) mexicana in the Yucatan peninsula, Mexico. Rev Inst Med Trop Sao Paulo 2005; 47:191-4.
114. Gutierrez Y, Salinas GH, Palma G, Valderrama LB, Santrich CV, Saravia NG. Correlation between histopathology, immune response, clinical presentation, and evolution in Leishmania braziliensis infection. Am J Trop Med Hyg 1991; 45:281-9.
115. Craig C, Faust E. Clinical parasitology. 3rd ed. Philadelphia, PA: Lea and Febiger, 1943.
116. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7:581-96.
117. Weigle K, Saravia NG. Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous leishmaniasis. Clin Dermatol 1996; 14:433-50.
118. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366:1561-77.
119. Blum J, Lockwood DNJ, Visser L, et al. Local or systemic treatment for New World cutaneous leishmaniasis Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health 2012; 4:153-63.
120. Singer C, Armstrong D, Jones TC, Spiro RH. Imported mucocutaneous leishmaniasis in New York City. Report of a patient treated with amphotericin B. Am J Med 1975; 59:444-7.
121. Maguire GP, Bastian I, Arianayagam S, Bryceson A, Currie BJ. NewWorld cutaneous leishmaniasis imported into Australia. Pathology 1998; 30:73-6.
122. Lohuis PJ, Lipovsky MM, Hoepelman AI, Hordijk GJ, Huizing EH. Leishmania braziliensis presenting as a granulomatous lesion of the nasal septum mucosa. J Laryngol Otol 1997; 111:973-5.
123. Rosbotham JL, Corbett EL, Grant HR, Hay RJ, Bryceson AD. Imported mucocutaneous leishmaniasis. Clin Exp Dermatol 1996; 21:288-90.
124. Blum J, Junghanss T, Hatz C. Erroneous tracks in the diagnosis of cutaneous and mucocutaneous leishmaniasis [in German]. Schweiz Rundsch Med Prax 1994; 83:1025-9.
125. Scope A, Trau H, Bakon M, Yarom N, Nasereddin A, Schwartz E. Imported mucosal leishmaniasis in a traveler. Clin Infect Dis 2003; 37:e83-7.
126. Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: An emerging health problem among British travellers. QJM 2004; 97:781-8.
127. Eichner S, Thoma-Uszynski S, Herrgott I, et al. Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers. Eur J Dermatol 2013; 23:218-23.
128. Bart A, van Thiel PP, de Vries HJ, Hodiamont CJ, Van Gool T. Imported leishmaniasis in the Netherlands from 2005 to 2012: Epidemiology, diagnostic techniques and sequence-based species typing from 195 patients. Euro Surveill 2013; 18:20544.
129. Lachaud L, Dedet JP, Marty P, et al. Surveillance of leishmaniases in France, 1999 to 2012. Euro Surveill 2013; 18:20534.
130. Neumayr ALC, Walter C, Stoeckle M, Braendle N, Glatz K, Blum JA. Successful treatment of imported mucosal Leishmania infantum leishmaniasis with miltefosine after severe hypokalemia under meglumine antimoniate treatment. J Travel Med 2012; 19:124-6.
131. Lawn SD, Yardley V, Vega-Lopez F, Watson J, Lockwood DN. New World cutaneous leishmaniasis in returned travellers: Treatment failures using intravenous sodium stibogluconate. Trans R Soc Trop Med Hyg 2003; 97:443-5.
132. Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006; 6:342-9.
133. Andrade-Narvaez FJ, Vargas-Gonzalez A, Canto-Lara SB, Damian-Centeno AG. Clinical picture of cutaneous leishmaniases due to Leishmania (Leishmania) mexicana in the Yucatan Peninsula, Mexico. Mem Inst Oswaldo Cruz 2001; 96:163-7.
134. Velasco O, Savarino SJ, Walton BC, Gam AA, Neva FA. Diffuse cutaneous leishmaniasis in Mexico. Am J Trop Med Hyg 1989; 41:280-8.
135. Richter J, Hanus I, Haussinger D, Loscher T, Harms G. Mucosal Leishmania infantum infection. Parasitol Res 2011; 109:959-62.
136. Velez I, Agudelo S, Robledo S, et al. Diffuse cutaneous leishmaniasis with mucosal involvement in Colombia, caused by an enzymatic variant of Leishmania panamensis. Trans R Soc Trop Med Hyg 1994; 88:199.
137. Bonfante-Garrido R, Barroeta S, de Alejos MA, et al. Disseminated American cutaneous leishmaniasis. Int J Dermatol 1996; 35:561-5.
138. Silveira FT, Lainson R, Corbett CE. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: A review. Mem Inst Oswaldo Cruz 2004; 99:239-51.
139. Zerpa O, Ulrich M, Blanco B, et al. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 2007; 156:1328-35.
140. Khamesipour A. Therapeutic vaccines for leishmaniasis. Expert Opin Biol Ther 2014; 14:1641-9.
141. Saravia NG, Weigle K, Segura I, et al. Recurrent lesions in human Leishmania braziliensis infection-reactivation or reinfection Lancet 1990; 336:398-402.
142. Netto EM, Marsden PD, Llanos-Cuentas EA, et al. Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime. Trans R Soc Trop Med Hyg 1990; 84:367-70.
143. Mendonca MG, de Brito ME, Rodrigues EH, Bandeira V, Jardim ML, Abath FG. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: Is there a sterile cure J Infect Dis 2004; 189:1018-23.
144. Paul BC, Rafii B, Achlatis S, Amin MR, Branski RC. Morbidity and patient perception of flexible laryngoscopy. Ann Otol Rhinol Laryngol 2012; 121:708-13.
145. Dimier-David L, David C, Munoz M, et al. Epidemiological, clinical and biological features of mucocutaneous leishmaniasis in Bolivia after a 221 patient sample [in French]. Bull Soc Pathol Exot 1993; 86:106-11.
146. Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N. The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 2000; 16:925-50.
147. Oliveira-Neto MP, Schubach A, Mattos M, da Costa SC, Pirmez C. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil-an area of Leishmania (V.) braziliensis transmission. Int J Dermatol 1997; 36:463-8.
148. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 1997; 57:651-5.
149. Camuset G, Remy V, Hansmann Y, Christmann D, Gomes de Albuquerque C, Sena Casseb GA. Mucocutaneous leishmaniasis in Brazilian Amazonia [in French]. Med Mal Infect 2007; 37:343-6.
150. Velez I, Agudelo S, Hendrickx E, et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 1997; 126:232-6.
151. D'Oliveira Junior A, Machado PR, Carvalho EM. Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis. Int J Dermatol 1997; 36:938-40.
152. Bourreau E, Ginouves M, Prevot G, et al. Presence of Leishmania RNA virus 1 in Leishmania guyanensis increases the risk of first-line treatment failure and symptomatic relapse. J Infect Dis 2016; 213:105-11.
153. Adaui V, Lye LF, Akopyants NS, et al. Association of the endobiont doublestranded RNA Virus LRV1 with treatment failure for human leishmaniasis caused by Leishmania braziliensis in Peru and Bolivia. J Infect Dis 2016; 213:112-21.
154. Machado P, Araujo C, Da Silva AT, et al. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis 2002; 34: E69-73.
155. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008; 46:223-31.
156. Solomon M, Pavlotzky F, Barzilai A, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol 2013; 68:284-9.
157. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266-72.
158. Dorlo TP, van Thiel PP, Huitema AD, et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008; 52:2855-60.
159. Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 2011; 25:973-7.
160. Wortmann G, Zapor M, Ressner R, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:1028-33.
161. Neves LO, Talhari AC, Gadelha EP, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol 2011; 86:1092-101.
162. Correia D, Macedo VO, Carvalho EM, et al. Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis [in Portuguese]. Rev Soc Bras Med Trop 1996; 29:447-53.
163. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, et al. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 2005; 72:133-7.
164. van der Meide WF, Sabajo LO, Jensema AJ, et al. Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname. Int J Dermatol 2009; 48:52-8.
165. Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994; 50:107-11.
166. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16:417-25.
167. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:528-34.
168. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990; 89:147-55.
169. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-5.
170. Morizot G, Delgiudice P, Caumes E, et al. Healing of OldWorld cutaneous leishmaniasis in travelers treated with fluconazole: Drug effect or spontaneous evolution Am J Trop Med Hyg 2007; 76:48-52.
171. Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized clinical trial. J Am Acad Dermatol 2011; 64:606-8.
172. Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD, Pompeu MM. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis 2011; 53:693-5.
173. Sacks DL, Barral A, Neva FA. Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro. Am J Trop Med Hyg 1983; 32:300-4.
174. Reithinger R, Mohsen M, Wahid M, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: A randomized, controlled trial. Clin Infect Dis 2005; 40:1148-55.
175. Safi N, Davis GD, Nadir M, Hamid H, Robert LL Jr, Case AJ. Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: A randomized controlled trial. Mil Med 2012; 177:345-51.
176. Aronson NE, Wortmann GW, Byrne WR, et al. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis 2010; 4:e628.
177. Sadeghian G, Nilfroushzadeh MA, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol 2007; 32:371-4.
178. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990; 42:43-50.
179. Lopez L, Robayo M, Vargas M, Velez ID. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 2012; 13:58.
180. al-Majali O, Routh HB, Abuloham O, Bhowmik KR, Muhsen M, Hebeheba H. A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int J Dermatol 1997; 36:460-2.
181. Salmanpour R, Razmavar MR, Abtahi N. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45:1115-6.
182. Negera E, Gadisa E, Hussein J, et al. Treatment response of cutaneous leishmaniasis due to Leishmania aethiopica to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia. Trans R Soc Trop Med Hyg 2012; 106:496-503.
183. Ranawaka RR, Weerakoon HS, Opathella N. Liquid nitrogen cryotherapy on Leishmania donovani cutaneous leishmaniasis. J Dermatolog Treat 2011; 22:241-5.
184. Al-Gindan Y, Kubba R, Omer AH, el-Hassan AM. Cryosurgery in Old World cutaneous leishmaniasis. Br J Dermatol 1988; 118:851-4.
185. Gurel MS, Ulukanligil M, Ozbilge H. Cutaneous leishmaniasis in Sanliurfa: Epidemiologic and clinical features of the last four years (1997-2000). Int J Dermatol 2002; 41:32-7.
186. Uzun S, Uslular C, Yucel A, Acar MA, Ozpoyraz M, Memisoglu HR. Cutaneous leishmaniasis: Evaluation of 3,074 cases in the Cukurova region of Turkey. Br J Dermatol 1999; 140:347-50.
187. Thomaidou E, Horev L, Jotkowitz D, et al. Lymphatic dissemination in cutaneous leishmaniasis following local treatment. Am J Trop Med Hyg 2015; 93:770-3.
188. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: A placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006; 31:634-7.
189. Enk CD, Nasereddin A, Alper R, Dan-Goor M, Jaffe CL, Wulf HC. Cutaneous leishmaniasis responds to daylight-activated photodynamic therapy: Proof of concept for a novel self-administered therapeutic modality. Br J Dermatol 2015; 172:1364-70.
190. Meymandi S, Zandi S, Aghaie H, Heshmatkhah A. Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate. J Eur Acad Dermatol Venereol 2011; 25:587-91.
191. Blum J, Buffet P, Visser L, et al. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. J Travel Med 2014; 21:116-29.
192. Reithinger R, Aadil K, Kolaczinski J, Mohsen M, Hami S. Social impact of leishmaniasis, Afghanistan. Emerg Infect Dis 2005; 11:634-6.
193. Ranawaka RR, Weerakoon HS. Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani. J Dermatolog Treat 2010; 21:286-93.
194. Alkhawajah AM, Larbi E, al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: Intramuscular versus intralesional administration. Ann Trop Med Parasitol 1997; 91:899-905.
195. Harms G, Chehade AK, Douba M, et al. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85:214-6.
196. Soto J, Rojas E, Guzman M, et al. Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis. Clin Infect Dis 2013; 56:1255-60.
197. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43:281-3.
198. El-On J, Livshin R, Even-Paz Z, Hamburger D, Weinrauch L. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986; 87:284-8.
199. Soto JM, Toledo JT, Gutierrez P, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): Phase 2 pilot study. Am J Trop Med Hyg 2002; 66:147-51.
200. Sosa N, Capitan Z, Nieto J, et al. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am J Trop Med Hyg 2013; 89:557-63.
201. Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 2009; 3:e381.
202. Shani-Adir A, Kamil S, Rozenman D, et al. Leishmania tropica in northern Israel: A clinical overview of an emerging focus. J Am Acad Dermatol 2005; 53:810-5.
203. Ben Salah A, Buffet PA, Morizot G, et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: A phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009; 3:e432.
204. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013; 368:524-32.
205. Schubach A, Marzochi MC, Cuzzi-Maya T, et al. Cutaneous scars in American tegumentary leishmaniasis patients: A site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am J Trop Med Hyg 1998; 58:824-7.
206. Oster CN, Chulay JD, Hendricks LD, et al. American cutaneous leishmaniasis: A comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg 1985; 34:856-60.
207. Herwaldt BL, Arana BA, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:518-27.
208. Akilov OE, Khachemoune A, Hasan T. Clinical manifestations and classification of Old World cutaneous leishmaniasis. Int J Dermatol 2007; 46:132-42.
209. Olliaro P, Vaillant M, Arana B, et al. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis 2013; 7: E2130.
210. Bouros D, Zeros G, Panaretos C, Vassilatos C, Siafakas N. Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux test). Chest 1991; 99:416-9.
211. Gonzalez U, Pinart M, Reveiz L, et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 2010; 51:409-19.
212. Sadeghian G, Ziaei H, Bidabadi LS, Baghbaderani AZ. Decreased effect of glucantime in cutaneous leishmaniasis complicated with secondary bacterial infection. Indian J Dermatol 2011; 56:37-9.
213. van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 2014; 20:286-99.
214. Amato VS, Tuon FF, Imamura R, Abegao de Camargo R, Duarte MI, Neto VA. Mucosal leishmaniasis: Description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 2009; 23:1026-34.
215. Casero R, Laconte L, Fraenza L, Iglesias N, Quinteros Greco C, Villablanca M. Recidivant laryngeal leishmaniasis: An unusual case in an immunocompetent patient treated with corticosteroids [in Spanish]. Rev Argent Microbiol 2010; 42:118-21.
216. Tuon FF, Sabbaga Amato V, Floeter-Winter LM, et al. Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids-first report. Int J Dermatol 2007; 46:628-30.
217. Marovich MA, Lira R, Shepard M, et al. Leishmaniasis recidivans recurrence after 43 years: A clinical and immunologic report after successful treatment. Clin Infect Dis 2001; 33:1076-9.
218. Kanj LF, Kibbi AG, Zaynoun S. Cutaneous leishmaniasis: An unusual case with atypical recurrence. J Am Acad Dermatol 1993; 28:495-6.
219. Gangneux JP, Sauzet S, Donnard S, et al. Recurrent American cutaneous leishmaniasis. Emerg Infect Dis 2007; 13:1436-8.
220. Mueller MC, Fleischmann E, Grunke M, Schewe S, Bogner JR, Loscher T. Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab. Am J Trop Med Hyg 2009; 81:52-4.
221. Valencia C, Arevalo J, Dujardin JC, Llanos-Cuentas A, Chappuis F, ZimicM. Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions. PLoS Negl Trop Dis 2012; 6:e1656.
222. Unger A, O'Neal S, Machado PR, et al. Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. Am J Trop Med Hyg 2009; 80:574-9.
223. Rodrigues AM, Hueb M, Santos TA, Fontes CJ. Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate [in Portuguese]. Rev Soc Bras Med Trop 2006; 39:139-45.
224. Mohammadzadeh M, Behnaz F, Golshan Z. Efficacy of glucantime for treatment of cutaneous leishmaniasis in central Iran. J Infect Public Health 2013; 6:120-4.
225. Torres DC, Ribeiro-Alves M, Romero GA, Davila AM, Cupolillo E. Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil. Acta Trop 2013; 126:132-41.
226. Ait-Oudhia K, Gazanion E, Vergnes B, Oury B, Sereno D. Leishmania antimony resistance: What we know what we can learn from the field. Parasitol Res 2011; 109:1225-32.
227. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006; 193:1375-83.
228. Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007; 44:1549-54.
229. Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: A randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007; 44:788-93.
230. Lessa HA, Machado P, Lima F, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 2001; 65:87-9.
231. de Oliveira-Neto MP, Mattos Mda S. An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable. Rev Soc Bras Med Trop 2006; 39:323-6.
232. Almeida RP, Brito J, Machado PL, et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am J Trop Med Hyg 2005; 73:79-81.
233. Hervas JA, Martin-Santiago A, Hervas D, et al. Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod. Pediatr Infect Dis J 2012; 31:97-100.
234. Obonaga R, Fernandez OL, Valderrama L, et al. Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. Antimicrob Agents Chemother 2014; 58:144-52.
235. Gunduz K, Afsar S, Ayhan S, et al. Recidivans cutaneous leishmaniasis unresponsive to liposomal amphotericin B (AmBisome). J Eur Acad Dermatol Venereol 2000; 14:11-3.
236. Purkait B, Singh R,Wasnik K, et al. Up-regulation of silent information regulator 2 (Sir2) is associated with amphotericin B resistance in clinical isolates of Leishmania donovani. J Antimicrob Chemother 2015; 70:1343-56.
237. Pimentel MI, Baptista C, Rubin EF, et al. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: A case report. Rev Soc Bras Med Trop 2011; 44:254-6.
238. Arevalo J, Ramirez L, Adaui V, et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 2007; 195:1846-51.
239. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006; 3:e162.
240. Utaile M, Kassahun A, Abebe T, Hailu A. Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model. Exp Parasitol 2013; 134:68-75.
241. Bafica A, Oliveira F, Freitas LA, Nascimento EG, Barral A. American cutaneous leishmaniasis unresponsive to antimonial drugs: Successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. Int J Dermatol 2003; 42:203-7.
242. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33:1847-51.
243. Baum KF, Berens RL. Successful treatment of cutaneous leishmaniasis with allopurinol after failure of treatment with ketoconazole. Clin Infect Dis 1994; 18:813-5.
244. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009; 2:CD004834.
245. Machado PR, Ho J, Bang H, Guimarães LH, Carvalho EM. Reply to Ojha et al. Clin Infect Dis 2007; 45:1.
246. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC. Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Tropica 2008; 105:1-9.
247. Oliveira-Neto MP, Mattos M, Pirmez C, et al. Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo 2000; 42:321-5.
248. Llanos-Cuentas A, Echevarria J, Cruz M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 1997; 25:677-84.
249. Costa JM, Netto EM, Marsden PD. Acute airway obstruction due to oedema of the larynx following antimony therapy in mucosal leishmaniasis. Rev Soc Bras Med Trop 1986; 19:109.
250. Rocha RA, Sampaio RN, Guerra M, et al. Apparent Glucantime failure in five patients with mucocutaneous leishmaniasis. J Trop Med Hyg 1980; 83:131-9.
251. Keith PJ, Wetter DA, Wilson JW, Lehman JS. Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses. Br J Dermatol 2014; 171:1307-17.
252. Shafran DM, Bunce PE, Gold WL. Reducing the risk of infection in a 74-year-old man who is to receive prednisone. CMAJ 2014; 186:1239-40.
253. Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: Report of three cases. Trans R Soc Trop Med Hyg 2007; 101:1163-5.
254. Mejia R, Nutman TB. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 2012; 25:458-63.
255. Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA. Treatment of mucosal leishmaniasis in Latin America: Systematic review. Am J Trop Med Hyg 2007; 77:266-74.
256. Saenz RE, de Rodriguez CG, Johnson CM, Berman JD. Efficacy and toxicity of pentostam against Panamanian mucosal leishmaniasis. Am J Trop Med Hyg 1991; 44:394-8.
257. Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990; 113:934-40.
258. Franke ED, Llanos-Cuentas A, Echevarria J, et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 1994; 51:77-82.
259. Brito G, Dourado M, Polari L, et al. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. Am J Trop Med Hyg 2014; 90:617-20.
260. Sampaio SA, Castro RM, Dillon NL, Martins JE. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: Report of 70 cases. Int J Dermatol 1971; 10:179-81.
261. Rodriguez LV, Dedet JP, Paredes V, Mendoza C, Cardenas F. A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 1995; 90:525-8.
262. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44:350-6.
263. Rocio C, Amato VS, Camargo RA, Tuon FF, Nicodemo AC. Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients. Trans R Soc Trop Med Hyg 2014; 108:176-8.
264. Amato VS, Tuon FF, Camargo RA, Souza RM, Santos CR, Nicodemo AC. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis Am J Trop Med Hyg 2011; 85:818-9.
265. Amato VS, Tuon FF, Campos A, et al. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin Infect Dis 2007; 44:311-2.
266. Lambertucci JR, Silva LC. Mucocutaneous leishmaniasis treated with liposomal amphotericin B. Rev Soc Bras Med Trop 2008; 41:87-8.
267. Sampaio RN, Marsden PD. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B [in Portuguese]. Rev Soc Bras Med Trop 1997; 30:125-8.
268. Cunha MA, Leao AC, de Cassia Soler R, Lindoso JA. Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the New World: A retrospective study. Am J Trop Med Hyg 2015; 93:1214-8.
269. Soto J, Rea J, Valderrama M, et al. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 2009; 81:387-9.
270. Garcia Bustos MF, Barrio A, Parodi C, Beckar J, Moreno S, Basombrio MA. Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis [in Spanish]. Medicina (B Aires) 2014; 74:371-7.
271. Briefing Document for the Anti-Infective Drugs Advisory Committee Meeting. Impavido® (miltefosine) capsules for the treatment of visceral, mucosal and cutaneous leishmaniasis. In: Anti-infective Drugs Advisory Committee Meeting Materials Advisory Committee Briefing Book 2013, 18 October 2013. Available at: Http://www.fda.gov/downloads/advisorycommittees/committeesmeeting materials/drugs/anti-infectivedrugsadvisorycommittee/ucm371075.pdf. Accessed 22 October 2016.
272. Llanos-Cuentas A, Echevarria J, Seas C, et al. Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis. Am J Trop Med Hyg 2007; 76:1128-31.
273. Romero GA, Lessa HA, Orge MG, Macedo VO, Marsden PD. Treatment of mucosal leishmaniasis with aminosidine sulfate: Results of two year follow-up [in Portuguese]. Rev Soc Bras Med Trop 1998; 31:511-6.
274. Tuon FF, Gomes-Silva A, Da-Cruz AM, Duarte MI, Neto VA, Amato VS. Local immunological factors associated with recurrence of mucosal leishmaniasis. Clin Immunol 2008; 128:442-6.
275. Hasker E, Malaviya P, Gidwani K, et al. Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal. PLoS Negl Trop Dis 2014; 8: E2657.
276. Monge-Maillo B, Lopez-Velez R. Therapeutic options for visceral leishmaniasis. Drugs 2013; 73:1863-88.
277. Berman J. Amphotericin B formulations and other drugs for visceral leishmaniasis. Am J Trop Med Hyg 2015; 92:471-3.
278. Saha AK, Mukherjee T, Bhaduri A. Mechanism of action of amphotericin B on Leishmania donovani promastigotes. Mol Biochem Parasitol 1986; 19:195-200.
279. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet 1992; 23:279-91.
280. Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003; 4:179-85.
281. Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F. Therapy of visceral leishmaniasis due to Leishmania infantum: Experimental assessment of efficacy of AmBisome. Antimicrob Agents Chemother 1996; 40:1214-8.
282. Gradoni L, Davidson RN, Orsini S, Betto P, Giambenedetti M. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J Drug Target 1993; 1:311-6.
283. Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (Am-Bisome) in Mediterranean visceral leishmaniasis: A multi-centre trial. Q J Med 1994; 87:75-81.
284. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28:42-8; discussion 9-51.
285. Seaman J, Boer C, Wilkinson R, et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995; 21:188-93.
286. Burza S, Sinha PK, Mahajan R, et al. Post kala-azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis 2014; 8:49.
287. Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22:938-43.
288. Syriopoulou V, Daikos GL, Theodoridou M, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003; 36:560-6.
289. Freire M, Badaro F, Avelar ME, et al. Efficacy and tolerability of liposomal amphotericin B (Ambisome) in the treatment of visceral leishmaniasis in Brazil. Braz J Infect Dis 1997; 1:230-40.
290. Khalil EAG, Weldegebreal T, Younis BM, et al. Safety and efficacy of single dose versus multiple doses of AmBisome(registered trademark) for treatment of visceral leishmaniasis in Eastern Africa: A randomised trial. PLoS Negl Trop Dis 2014; 8:21.
291. Salih NAW, van Griensven J, Chappuis F, et al. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: How effective is treatment for this neglected disease Trop Med Int Health 2014; 19:146-52.
292. Mueller YK, Kolaczinski JH, Koech T, et al. Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya. Am J Trop Med Hyg 2014; 90:33-9.
293. Dietze R, Milan EP, Berman JD, et al. Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis 1993; 17:981-6.
294. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, lowdose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997; 127:133-7.
295. Gaeta GB, Maisto A, Di Caprio D, et al. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients. Scand J Infect Dis 2000; 32:675-7.
296. Dietze R, Fagundes SM, Brito EF, et al. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995; 89:309-11.
297. Sundar S, Goyal AK, Mandal AK, Makharia MK, Singh VP, Murray HW. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis. J Assoc Physicians India 1999; 47:186-8.
298. Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Treatment of antimonyunresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol 1998; 92:755-64.
299. Sundar S, Mehta H, Chhabra A, et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis 2006; 42:608-13.
300. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations. Clin Infect Dis 2004; 38:377-83.
301. Thakur CP, Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 2004; 98:129-38.
302. Thakur CP, Sinha GP, Pandey AK, Barat D, Singh RK. Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: A randomized comparison. Bull World Health Organ 1994; 72:931-6.
303. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: A systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005; 5:763-74.
304. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994; 344:1599-600.
305. Sundar S, Chakravarty J, Rai VK, et al. Amphotericin B treatment for Indian visceral leishmaniasis: Response to 15 daily versus alternate-day infusions. Clin Infect Dis 2007; 45:556-61.
306. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007; 356:2571-81.
307. Szebeni J. Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology 2005; 216:106-21.
308. Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: Analysis of clinical and epidemiological characteristics. Clin Infect Dis 2003; 36:1213-20.
309. Farmakiotis D, Tverdek FP, Kontoyiannis DP. The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B. Clin Infect Dis 2013; 56:701-3.
310. Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007; 196:591-8.
311. Singh UK, Prasad R, Mishra OP, Jayswal BP. Miltefosine in children with visceral leishmaniasis: A prospective, multicentric, cross-sectional study. Indian J Pediatr 2006; 73:1077-80.
312. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003; 22:434-8.
313. Monge-Maillo B, Lopez-Velez R. Miltefosine for visceral and cutaneous leishmaniasis: Drug characteristics and evidence-based treatment recommendations. Clin Infect Dis 2015; 60:1398-404.
314. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
315. Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352:1821-3.
316. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-7.
317. Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: Determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004; 38:612-9.
318. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-800.
319. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006; 43:357-64.
320. Carnielli JB, de Andrade HM, Pires SF, et al. Proteomic analysis of the soluble proteomes of miltefosine-sensitive and-resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes. J Proteomics 2014; 108:198-208.
321. Prajapati VK, Mehrotra S, Gautam S, Rai M, Sundar S. In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis-status of newly introduced drugs. Am J Trop Med Hyg 2012; 87:655-7.
322. Bhandari V, Kulshrestha A, Deep DK, et al. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis 2012; 6:e1657.
323. Rijal S, Ostyn B, Uranw S, et al. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 2013; 56:1530-8.
324. Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012; 55:543-50.
325. Rijal S, Chappuis F, Singh R, et al. Treatment of visceral leishmaniasis in southeastern Nepal: Decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 2003; 97:350-4.
326. Musa A, Khalil E, Hailu A, et al. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: A randomised controlled trial. PLoS Negl Trop Dis 2012; 6:e1674.
327. Brustoloni YM, Cunha RV, Consolo LZ, Oliveira AL, Dorval ME, Oshiro ET. Treatment of visceral leishmaniasis in children in the central-west region of Brazil. Infection 2010; 38:261-7.
328. de Melo EC, Fortaleza CM. Challenges in the therapy of visceral leishmaniasis in Brazil: A public health perspective. J Trop Med 2013; 2013:319234.
329. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992; 340:1256-7.
330. Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: A randomized study. Am J Trop Med Hyg 1991; 45:435-41.
331. Sundar S, Singh VP, Agrawal NK, Gibbs DL, MurrayHW. Treatment of kala-azar with oral fluconazole. Lancet 1996; 348:614.
332. Bechade D, Seurat L, Discamps G, Taniere PH, Du Bourguet F. Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: Favourable course with itraconazole [in French]. Rev Med Interne 1996; 17:234-7.
333. Maru M. Clinical and laboratory features and treatment of visceral leishmaniasis in hospitalized patients in northwestern Ethiopia. Am J Trop Med Hyg 1979; 28:15-8.
334. Kager PA, Rees PH, Manguyu FM, et al. Clinical, haematological and parasitological response to treatment of visceral leishmaniasis in Kenya. A study of 64 patients. Trop Geogr Med 1984; 36:21-35.
335. Zijlstra EE. The treatment of kala-azar: Old and new options. Trop Geogr Med 1992; 44:288.
336. Caldas AJ, Costa J, Aquino D, Silva AA, Barral-Netto M, Barral A. Are there differences in clinical and laboratory parameters between children and adults with American visceral leishmaniasis Acta Tropica 2006; 97:252-8.
337. Cascio A, di Martino L, Occorsio P, et al. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: The Italian experience. J Antimicrob Chemother 2004; 54:217-20.
338. Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998; 76:25-32.
339. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362:504-12.
340. di Martino L, Davidson RN, Giacchino R, et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997; 131:271-7.
341. Nyakundi PM, Wasunna KM, Rashid JR, et al. Is one year follow-up justified in kala-azar post-treatment East Afr Med J 1994; 71:453-9.
342. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomised trial. BMJ 2001; 323:419-22.
343. Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008; 47:1000-6.
344. Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection 2003; 31:174-7.
345. Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996; 124:664-72.
346. Mueller Y, Mbulamberi DB, Odermatt P, Hoffmann A, Loutan L, Chappuis F. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop Med Int Health 2009; 14:910-7.
347. Sampaio MJ, Cavalcanti NV, Alves JG, Filho MJ, Correia JB. Risk factors for death in children with visceral leishmaniasis. PLoS Negl Trop Dis 2010; 4:e877.
348. Antinori S, Longhi E, Bestetti G, et al. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 2007; 157:1032-6.
349. Maurya R, Singh RK, Kumar B, Salotra P, Rai M, Sundar S. Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure. J Clin Microbiol 2005; 43:3038-41.
350. Cascio A, Calattini S, Colomba C, et al. Polymerase chain reaction in the diagnosis and prognosis of Mediterranean visceral leishmaniasis in immunocompetent children. Pediatrics 2002; 109:E27.
351. Fisa R, Riera C, Ribera E, Gallego M, Portus M. A nested polymerase chain reaction for diagnosis and follow-up of human visceral leishmaniasis patients using blood samples. Trans R Soc Trop Med Hyg 2002; 96(suppl 1):S191-4.
352. Disch J, Oliveira MC, Orsini M, Rabello A. Rapid clearance of circulating Leishmania kinetoplast DNA after treatment of visceral leishmaniasis. Acta tropica 2004; 92:279-83.
353. Nuzum E, White F 3rd, Thakur C, et al. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood. J Infect Dis 1995; 171:751-4.
354. Houghton RL, Petrescu M, Benson DR, et al. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis 1998; 177:1339-44.
355. Bern C, Jha SN, Joshi AB, Thakur GD, Bista MB. Use of the recombinant K39 dipstick test and the direct agglutination test in a setting endemic for visceral leishmaniasis in Nepal. Am J Trop Med Hyg 2000; 63:153-7.
356. De Almeida Silva L, Romero HD, Prata A, et al. Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg 2006; 75:739-43.
357. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003; 3:87-98.
358. Mueller YK, Nackers F, Ahmed KA, et al. Burden of visceral leishmaniasis in villages of eastern Gedaref State, Sudan: An exhaustive cross-sectional survey. PLoS Negl Trop Dis 2012; 6:e1872.
359. Ramesh V, Kaushal H, Mishra AK, Singh R, Salotra P. Clinico-epidemiological analysis of post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: A hospital based retrospective study. BMC Public Health 2015; 15:1092.
360. Ganguly S, Saha P, Chatterjee M, et al. PKDL-a silent parasite pool for transmission of leishmaniasis in kala-azar endemic areas of Malda District,West Bengal, India. PLoS Negl Trop Dis 2015; 9:e0004138.
361. World Health Organization. The post kala-azar dermal leishmaniasis (PKDL) atlas: A manual for health workers. Available at: Http://apps.who.int/iris/bitstream/10665/101164/1/9789241504102_eng.pdf. 2011. Accessed 22 October 2016.
362. Murray HW. Leishmaniasis in the United States: Treatment in 2012. Am J Trop Med Hyg 2012; 86:434-40.
363. Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 2009; 48:e16-22.
364. Alexandrino-de-Oliveira P, Santos-Oliveira JR, Dorval ME, et al. HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in central-west Brazil. Mem Inst Oswaldo Cruz 2010; 105:692-7.
365. Ritmeijer K, ter Horst R, Chane S, et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 2011; 53:e152-8.
366. Sinha PK, van Griensven J, Pandey K, et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 2011; 53:e91-8.
367. Burza S, Sinha PK, Mahajan R, et al. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis 2014; 8:46.
368. Burza S, Mahajan R, Sinha PK, et al. Visceral leishmaniasis and HIV co-infection in Bihar, India: Long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLoS Negl Trop Dis 2014; 8:e3053.
369. Laguna F, Torre-Cisneros J, Moreno V, Villanueva JL, Valencia E. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:711-2.
370. Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996; 32:133-7.
371. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97(suppl 1):135-42.
372. Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006; 43:917-24.
373. Cota GF, de Sousa MR, Fereguetti TO, Rabello A. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: A systematic review with indirect comparison. PLoS Negl Trop Dis 2013; 7:e2195.
374. Delgado J, Macias J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg 1999; 61:766-9.
375. Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia. PLoS Negl Trop Dis 2014; 8:e2875.
376. Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999; 13:1063-9.
377. Laguna F, Videla S, Jimenez-Mejias ME, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: A randomized pilot study. J Antimicrob Chemother 2003; 52:464-8.
378. Sindermann H, Engel KR, Fischer C, Bommer W. Oral miltefosine for leishmaniasis in immunocompromised patients: Compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004; 39:1520-3.
379. Troya J, Casquero A, Refoyo E, Fernandez-Guerrero ML, Gorgolas M. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis 2008; 40:78-80.
380. Marques N, Sa R, Coelho F, Oliveira J, Saraiva Da Cunha J, Melico-Silvestre A. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients. Scand J Infect Dis 2008; 40:523-6.
381. Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J. Visceral leishmaniasis and HIV coinfection in East Africa. PLoS Negl Trop Dis 2014; 8:e2869.
382. Mahajan R, Das P, Isaakidis P, et al. Combination treatment for visceral leishmaniasis patients coinfected with human immunodeficiency virus in India. Clin Infect Dis 2015; 61:1255-62.
383. Lopez-Velez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasitol 2003; 97(suppl 1):143-7.
384. Russo R, Laguna F, Lopez-Velez R, et al. Visceral leishmaniasis in those infected with HIV: Clinical aspects and other opportunistic infections. Ann Trop Med Parasitol 2003; 97(suppl 1):99-105.
385. del Giudice P, Mary-Krause M, Pradier C, et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002; 186:1366-70.
386. de la Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001; 32:633-5.
387. de La Rosa R, Pineda JA, Delgado J, et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 2002; 40:762-7.
388. Tortajada C, Perez-Cuevas B, Moreno A, et al. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIVinfected patients. J Acquir Immune Defic Syndr 2002; 30:364-6.
389. van Griensven J, Diro E, Lopez-Velez R, et al. HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. Lancet Infect Dis 2013; 13:251-9.
390. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: Repercussions for resourcelimited countries. J Infect Dis 2008; 198:948-61.
391. Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr Opin Infect Dis 2007; 20:482-8.
392. Badaro R, Goncalves LO, Gois LL, Maia ZP, Benson C, Grassi MF. Leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients: A literature review. J Int Assoc Provid AIDS Care 2015; 14:402-7.
393. Albrecht H. Leishmaniosis-new perspectives on an underappreciated opportunistic infection. AIDS 1998; 12:2225-6.
394. Jimenez-Exposito MJ, Alonso-Villaverde C, Sarda P, Masana L. Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy. AIDS 1999; 13:152-3.
395. Berry A, Abraham B, Dereure J, Pinzani V, Bastien P, Reynes J. Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy. Scand J Infect Dis 2004; 36:225-7.
396. Belay AD, Asafa Y, Mesure J, Davidson RN. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy. Ann Trop Med Parasitol 2006; 100:223-7.
397. Tadesse A, Hurissa Z. Leishmaniasis (PKDL) as a case of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive patient after initiation of anti-retroviral therapy (ART). Ethiop Med J 2009; 47:77-9.
398. Gilad J, Borer A, Hallel-Halevy D, Riesenberg K, Alkan M, Schlaeffer F. Postkala- A zar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Isr Med Assoc J 2001; 3:451-2.
399. Bourgeois N, Bastien P, Reynes J, Makinson A, Rouanet I, Lachaud L. 'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med 2010; 11:670-3.
400. Lopez-Velez R, Videla S, Marquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53:540-3.
401. Molina I, Falco V, Crespo M, et al. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2007; 60:837-42.
402. Perez-Molina JA, Lopez-Velez R, Montilla P, Guerrero A. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients. AIDS 1996; 10:237-8.
403. Patel TA, Lockwood DN. Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: Report of four cases. Trop Med Int Health 2009; 14:1064-70.
404. Diro E, Ritmeijer K, Boelaert M, et al. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients: The first twelve months of a prospective cohort study. PLoS Negl Trop Dis 2015; 9: E0004087.
405. Ribera E, Ocana I, de Otero J, Cortes E, Gasser I, Pahissa A. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996; 100:496-501.
406. Cojean S, Houze S, Haouchine D, et al. Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis 2012; 18:704-6.
407. Berenguer J, Cosin J, Miralles P, Lopez JC, Padilla B. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 2000; 14:2946-8.
408. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concordant HIV infection and visceral leishmaniasis in Ethiopia: The influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46:1702-9.
409. Villanueva JL, Alarcon A, Bernabeu-Wittel M, et al. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2000; 19:798-801.
410. Faucher B, Pomares C, Fourcade S, et al. Mucosal Leishmania infantum leishmaniasis: Specific pattern in a multicentre survey and historical cases. J Infect 2011; 63:76-82.
411. Aliaga L, Cobo F, Mediavilla JD, et al. Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: Clinical and microbiologic findings in 31 patients. Medicine (Baltimore) 2003; 82:147-58.
412. Cascio A, Antinori S, Campisi G, Mancuso S. Oral leishmaniasis in an HIV-infected patient. Eur J Clin Microbiol Infect Dis 2000; 19:651-3.
413. Madeddu G, Fiori ML, Ena P, et al. Mucocutaneous leishmaniasis as presentation of HIV infection in Sardinia, insular Italy. Parasitol Int 2014; 63:35-6.
414. Miralles ES, Nunez M, Hilara Y, Harto A, Moreno R, Ledo A. Mucocutaneous leishmaniasis and HIV. Dermatology 1994; 189:275-7.
415. Machado ES, Braga Mda P, Da Cruz AM, et al. Disseminated American mucocutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: A case report. Mem Inst Oswaldo Cruz 1992; 87:487-92.
416. Sampaio RN, Salaro CP, Resende P, de Paula CD. American cutaneous leishmaniasis associated with HIV/AIDS: Report of four clinical cases [in Portuguese]. Rev Soc Bras Med Trop 2002; 35:651-4.
417. Amato VS, Nicodemo AC, Amato JG, Boulos M, Neto VA. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). J Antimicrob Chemother 2000; 46:341-2.
418. Amato VS, Rabello A, Rotondo-Silva A, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Tropica 2004; 92:127-32.
419. Pérez C, Solias Y, Rodriguez G. Diffuse cutaneous leishmaniasis in a patient with AIDS [in Spanish]. Biomedica 2006; 26:485-97.
420. Schraner C, Hasse B, Hasse U, et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 2005; 40:e120-4.
421. Posada-Vergara MP, Lindoso JA, Tolezano JE, Pereira-Chioccola VL, Silva MV, Goto H. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis 2005; 192: 1819-22.
422. Chrusciak-Talhari A, Ribeiro-Rodrigues R, Talhari C, et al. Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. Am J Trop Med Hyg 2009; 81:559-64.
423. Sarazin E, Nacher M, Toure Y, et al. Dermatologic manifestations associated with immune reconstitution syndrome in HIV+ patients starting HAART: A retrospective study in French Guiana [in French]. Bull Soc Pathol Exot 2005; 98:187-92.
424. Sinha S, Fernandez G, Kapila R, Lambert WC, Schwartz RA. Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J Dermatol 2008; 47:1263-70.
425. Kerob D, Bouaziz JD, Sarfati C, et al. First case of cutaneous reconstitution inflammatory syndrome associated with HIV infection and leishmaniasis. Clin Infect Dis 2006; 43:664-6.
426. Blanche P, Gombert B, Rivoal O, Abad S, Salmon D, Brezin A. Uveitis due to Leishmania major as part of HAART-induced immune restitution syndrome in a patient with AIDS. Clin Infect Dis 2002; 34:1279-80.
427. Gois L, Badaro R, Schooley R, Grassi MF. Immune response to Leishmania antigens in an AIDS patient with mucocutaneous leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS): A case report. BMC Infect Dis 2015; 15:38.
428. Pavli A, Maltezou HC. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis 2010; 14:e1032-9.
429. Gautret P, Cramer JP, Field V, et al. Infectious diseases among travellers and migrants in Europe, EuroTravNet 2010. Euro Surveill 2012; 17.
430. Flores-Figueroa J, Okhuysen PC, von Sonnenburg F, et al. Patterns of illness in travelers visiting Mexico and Central America: The GeoSentinel experience. Clin Infect Dis 2011; 53:523-31.
431. Perez-Ayala A, Norman F, Perez-Molina JA, Herrero JM, Monge B, Lopez-Velez R. Imported leishmaniasis: A heterogeneous group of diseases. J Travel Med 2009; 16:395-401.
432. Buonomano R, Brinkmann F, Leupin N, et al. Holiday souvenirs from the Mediterranean: Three instructive cases of visceral leishmaniasis. Scand J Infect Dis 2009; 41:777-81.
433. Martin-Davila P, Fortun J, Lopez-Velez R, et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008; 21:60-96.
434. Coster LO. Parasitic infections in solid organ transplant recipients. Infect Dis Clin North Am 2013; 27:395-427.
435. Arce A, Estirado A, Ordobas M, et al. Re-emergence of leishmaniasis in Spain: Community outbreak in Madrid, Spain, 2009 to 2012. Euro Surveill 2013; 18:20546.
436. Larocca L, La Rosa R, Montineri A, et al. Visceral leishmaniasis in an Italian heart recipient: First case report. J Heart Lung Transplant 2007; 26:1347-8.
437. Frapier JM, Abraham B, Dereure J, Albat B. Fatal visceral leishmaniasis in a heart transplant recipient. J Heart Lung Transplant 2001; 20:912-3.
438. Golino A, Duncan JM, Zeluff B, et al. Leishmaniasis in a heart transplant patient. J Heart Lung Transplant 1992; 11(4 pt 1):820-3.
439. Morales P, Torres JJ, Salavert M, Peman J, Lacruz J, Sole A. Visceral leishmaniasis in lung transplantation. Transplant Proc 2003; 35:2001-3.
440. Clemente W, Vidal E, Girao E, et al. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: A retrospective multicenter case-control study. Clin Microbiol Infect 2015; 21:89-95.
441. Pittalis S, Nicastri E, Spinazzola F, et al. Leishmania infantum leishmaniasis in corticosteroid-treated patients. BMC Infect Dis 2006; 6:177.
442. Fletcher K, Issa R, Lockwood DN. Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: A changing pattern at the hospital for tropical diseases, London. PLoS One 2015; 10: E0121418.
443. Fernandez-Guerrero ML, Aguado JM, Buzon L, et al. Visceral leishmaniasis in immunocompromised hosts. Am J Med 1987; 83:1098-102.
444. Zanger P, Kotter I, Kremsner PG, Gabrysch S. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect 2012; 18:670-6.
445. Herrador Z, Gherasim A, Jimenez BC, Granados M, San Martin JV, Aparicio P. Epidemiological changes in leishmaniasis in Spain according to hospitalizationbased records, 1997-2011: Raising awareness towards leishmaniasis in non-HIV patients. PLoS Negl Trop Dis 2015; 9:e0003594.
446. Giavedoni P, Iranzo P, Fuertes I, Estrach T, Alsina Gibert M. Cutaneous leishmaniasis: 20 years' experience in a Spanish tertiary care hospital. Actas Dermosifiliogr 2015; 106:310-6.
447. Kopterides P, Mourtzoukou EG, Skopelitis E, Tsavaris N, Falagas ME. Aspects of the association between leishmaniasis and malignant disorders. Trans R Soc Trop Med Hyg 2007; 101:1181-9.
448. Fernandez-Guerrero ML, Robles P, Rivas P, Mojer F, Muniz G, de Gorgolas M. Visceral leishmaniasis in immunocompromised patients with and without AIDS: A comparison of clinical features and prognosis. Acta Trop 2004; 90:11-6.
449. Schwartz BS, Mawhorter SD. Parasitic infections in solid organ transplantation. Am J Transplant 2013; 13(suppl 4):280-303.
450. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at: Http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 22 October 2016.
451. Morizot G, Jouffroy R, Faye A, et al. Antimony to cure visceral leishmaniasis unresponsive to liposomal amphotericin B. PLoS Negl Trop Dis 2016; 10: E0004304.
452. Neumayr ALC, Morizot G, Visser LG, et al. Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-(alpha) antagonists. Travel Med Infect Dis 2013; 11:412-20.
453. Veroux M, Corona D, Giuffrida G, et al. Visceral leishmaniasis in the early posttransplant period after kidney transplantation: Clinical features and therapeutic management. Transpl Infect Dis 2010; 12:387-91.
454. Simon I, Wissing KM, Del Marmol V, et al. Recurrent leishmaniasis in kidney transplant recipients: Report of 2 cases and systematic review of the literature. Transpl Infect Dis 2011; 13:397-406.
455. Clemente WT, Rabello A, Faria LC, et al. High prevalence of asymptomatic Leishmania spp. infection among liver transplant recipients and donors from an endemic area of Brazil. Am J Transplant 2014; 14:96-101.
456. Silva JSF, Galvao TF, Pereira MG, Silva MT. Treatment of American tegumentary leishmaniasis in special populations: A summary of evidence. Rev Soc Bras Med Trop 2013; 46:669-77.
457. Figueiro-Filho EA, Duarte G, El-Beitune P, Quintana SM, Maia TL. Visceral leishmaniasis (kala-azar) and pregnancy. Infect Dis Obstet Gynecol 2004; 12:31-40.
458. Figueiro-Filho EA, El Beitune P, Queiroz GT, et al. Visceral leishmaniasis and pregnancy: Analysis of cases reported in a central-western region of Brazil. Arch Gynecol Obstet 2008; 278:13-6.
459. Mueller M, Balasegaram M, Koummuki Y, Ritmeijer K, Santana MR, Davidson R. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 2006; 58:811-5.
460. Adam GK, Abdulla MA, Ahmed AA, Adam I. Maternal and perinatal outcomes of visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan. Int J Gynaecol Obstet 2009; 107:208-10.
461. Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: A case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55:229-33.
462. Gradoni L, Gaeta GB, Pellizzer G, Maisto A, Scalone A. Mediterranean visceral leishmaniasis in pregnancy. Scand J Infect Dis 1994; 26:627-9.
463. Caldas AJ, Costa JM, Gama ME, Ramos EA, Barral A. Visceral leishmaniasis in pregnancy: A case report. Acta Tropica 2003; 88:39-43.
464. Topno RK, Pandey K, Das VN, et al. Visceral leishmaniasis in pregnancy-the role of amphotericin B. Ann Trop Med Parasitol 2008; 102:267-70.
465. Thakur CP, Sinha GP, Sharma V, Barat D. The treatment of kala-azar during pregnancy. Natl Med J India 1993; 6:263-5.
466. Paumgartten FJ, Chahoud I. Embryotoxicity of meglumine antimoniate in the rat. Reprod Toxicol 2001; 15:327-31.
467. Lima MI, Arruda VO, Alves EV, de Azevedo AP, Monteiro SG, Pereira SR. Genotoxic effects of the antileishmanial drug Glucantime. Arch Toxicol 2010; 84:227-32.
468. Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100(suppl 1):S17-20.
469. Food and Drug Administration. Miltefosine. Highlights of prescribing information. Revised March 2014. Available at: Http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204684s000lbl.pdf. Accessed 22 October 2016.
470. Dorlo TPC, Balasegaram M, Lima MA, De Vries PJ, Beijnen JH, Huitema ADR. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. J Antimicrob Chemother 2012; 67:1996-2004.
471. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 2012; 67:2576-97.
472. van Thiel PP, Leenstra T, Kager PA, et al. Miltefosine treatment of Leishmania major infection: An observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 2010; 50:80-3.
473. Valesky EM, Thaci D, Meissner M, et al. Cutaneous leishmaniasis: Clinical report of two cases and review of the recent literature. J Dtsch Dermatol Ges 2007; 5:770-2.
474. Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: Exuberant lesions and potential fetal complications. Clin Infect Dis 2007; 45:478-82.
475. Guimaraes LH, Machado PR, Lago EL, et al. Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, Brazil. Trans R Soc Trop Med Hyg 2009; 103:712-5.
476. Conceicao-Silva F, Morgado FN, Pimentel MIF, et al. Two women presenting worsening cutaneous ulcers during pregnancy: Diagnosis, immune response, and follow-up. PLoS Negl Trop Dis 2013; 7:e2472.
477. Ilett KF, Kristensen JH. Drug use and breastfeeding. Expert Opin Drug Saf 2005; 4:745-68.
478. Berman JD, Melby PC, Neva FA. Concentration of Pentostam in human breast milk. Trans R Soc Trop Med Hyg 1989; 83:784-5.
479. Solomon M, Schwartz E, Pavlotsky F, Sakka N, Barzilai A, Greenberger S. Leishmania tropica in children: A retrospective study. J Am Acad Dermatol 2014; 71:271-7.
480. Burden-Teh E, Wootton CI, Williams HC. Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children A critically appraised topic. Br J Dermatol 2015; 172:861-6.
481. Esfandiarpour I, Farajzadeh S, Rahnama Z, Fathabadi EA, Heshmatkhah A. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis. Int J Dermatol 2012; 51:1221-5.
482. Singh UK, Prasad R, Jaiswal BP, Singh PK, Thakur CP. Amphotericin B therapy in children with visceral leishmaniasis: Daily vs. alternate day, a randomized trial. J Trop Pediatr 2010; 56:321-4.
483. Minodier P, Robert S, Noel G, Blanc P, Retornaz K, Garnier JM. First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France [in French]. Arch Pediatr 2005; 12:1102-8.
484. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species. Am J Trop Med Hyg 2001; 64:187-93.
485. Rubiano LC, Miranda MC, Muvdi Arenas S, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 2012; 205:684-92.
486. Layegh P, Rahsepar S, Rahsepar AA. Systemic meglumine antimoniate in acute cutaneous leishmaniasis: Children versus adults. Am J Trop Med Hyg 2011; 84:539-42.
487. Cruz A, Rainey PM, Herwaldt BL, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 2007; 195:602-8.
488. Food and Drug Administration. Miltefosine (Impavido® ) for the treatment of visceral, mucosal and cutaneous leishmaniasis. In: FDA briefing document for the Anti-infective Drugs Advisory Committee Meeting, 18 October 2013. Available at: Http://www.fda.gov/downloads/advisorycommittees/committeesmeeting materials/drugs/anti-infectivedrugsadvisorycommittee/ucm371074.pdf. Accessed 22 October 2016.
489. Machado PR, Ampuero J, Guimaraes LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: A randomized and controlled trial. PLoS Negl Trop Dis 2010; 4:e912.
490. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84:255-60.
491. Bhattacharya SK, Jha TK, Sundar S, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004; 38:217-21.
492. Rahman M, Ahmed BN, Faiz MA, et al. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg 2011; 85:66-9.
493. Ostyn B, Hasker E, Dorlo TP, et al. Failure of miltefosine treatment for visceral leishmaniasis in children and men in south-east Asia. PLoS One 2014; 9:e100220.
494. Dorlo TPC, Huitema ADR, Beijnen JH, De Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob Agents Chemother 2012; 56:3864-72.
495. Dorlo TP, Rijal S, Ostyn B, et al. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. J Infect Dis 2014; 210:146-53.
496. Vasconcellos EC, Pimentel MI, Schubach AO, et al. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). Am J Trop Med Hyg 2012; 87:257-60.
497. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46:296-306.
498. Chappuis F, Alirol E, Worku DT, Mueller Y, Ritmeijer K. High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B. Antimicrob Agents Chemother 2011; 55:455-6.
499. Diniz DS, Costa AS, Escalda PM. The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil. Rev Soc Bras Med Trop 2012; 45:597-600.
500. Oliveira LF, Schubach AO, Martins MM, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica 2011; 118:87-96.
501. Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006; 100:264-9.
502. Wise ES, Armstrong MS, Watson J, Lockwood DN. Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]. PLoS Negl Trop Dis 2012; 6:e1688.
503. Chulay JD, Spencer HC, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985; 34:702-9.